Narapril

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Narapril

Property Description
Active ingredient Enalapril maleate
Form Oral tablets
Pharmacological class Angiotensin-Converting Enzyme (ACE) inhibitor
Common use Management of high blood pressure
Origin Synthetic compound (Prodrug)

What Type of Drug is Narapril and Its Core Classification?

Narapril is a prescription-only medication classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which is a primary group of antihypertensive agents used for cardiovascular support. Its pharmacological action involves modulating the hormonal system responsible for regulating blood pressure. This classification is central to the drug's purpose in maintaining healthy blood pressure, a role clinically recognized for decades across major medical guidelines. This synthetic compound is provided as a pharmaceutical preparation in the form of oral tablets, designed for systemic effect following ingestion.


Composition, Origin, and the Prodrug Identity

The active ingredient in Narapril is Enalapril maleate, a specific salt form of Enalapril. This substance is structurally a prodrug, meaning it is initially administered in an inactive form and must undergo metabolic conversion within the liver to become the potent, active chemical, Enalaprilat. This necessary conversion, which is a differentiating factor from certain older ACE inhibitors, dictates its oral route of administration and is a key feature of its identity. The Enalapril maleate component is manufactured as a synthetic compound.


General Purpose and Benefit of an ACE Inhibitor

The general purpose of Narapril is to achieve a sustained decrease in blood pressure by facilitating the widening of blood vessels, a process known as vasodilation. It accomplishes this by preventing a specific enzyme, ACE, from generating Angiotensin II, a powerful chemical signal that normally causes arteries to tighten and restrict blood flow. This targeted action reduces the overall peripheral vascular resistance, thereby lowering the strain placed on the heart and improving circulatory function. The use of an ACE inhibitor like Enalapril is a typical, foundational strategy for patients requiring long-term management of high systemic pressure.

Regulatory References

  1. NIH MedlinePlus ACE Inhibitors

What side effects are possible with Narapril?

Possible Side Effects and Safety Information

This section describes the officially documented adverse effects and safety characteristics of Enalapril maleate (Narapril), strictly based on government regulatory classifications. The safety profile is structured by frequency, the physiological system affected, and the severity of the reaction.


Adverse Reactions by Frequency and System

The most frequently observed adverse reactions are categorized in regulatory documents:

  • Very Common (ge1/10): These include dizziness and cough. The cough associated with this class of medication may be persistent.
  • Common (ge1/100 to <1/10): Reactions often affecting the vascular, nervous, or gastrointestinal systems, such as hypotension (low blood pressure), headache, fatigue, nausea, diarrhea, and rash.

Serious Adverse Reactions officially listed in regulatory labeling include angioedema (swelling of the face, tongue, and throat) and rare events such as hepatic failure and acute renal failure.


Population Safety Notes and Constraints

Certain safety statements are specific to patient populations or conditions:

  • Fetal Toxicity: The medication is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus.
  • Hypersensitivity: It is contraindicated in individuals with a history of angioedema related to any previous treatment with an ACE inhibitor.
  • Time-Related Pattern: Symptomatic hypotension may occur more frequently at the start of therapy in patients who are volume-depleted or have pre-existing severe heart failure.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Narapril (Enalapril maleate) is officially characterized by severe hemodynamic instability, according to government regulatory documentation.

Domain Documented Regulatory Statements
Documented Manifestations The most frequent and pronounced signs are profound hypotension, dizziness, light-headedness, tachycardia (accelerated heart rate), and bradycardia (slowed heart rate).
Severe Outcomes Excessive exposure may lead to life-threatening complications, including circulatory shock, acute renal failure, stupor (altered consciousness), and hyperkalemia (abnormally high serum potassium levels).
Emergency Action Immediate medical attention must be sought if an overdose is suspected. Hospitalization and continuous monitoring of blood pressure and laboratory values are officially required.
Supportive Management Treatment is documented as symptomatic and supportive. As no specific antidote is known, procedures such as intravenous volume expansion with normal saline, Angiotensin II infusion, and hemodialysis (the active metabolite is dialyzable) may be necessary to stabilize the patient.

Regulatory Context for Seeking Urgent Help

Regulatory guidance dictates that the documented severity of these manifestations requires urgent medical intervention. The primary danger—profound hypotension—directly necessitates stabilization and continuous monitoring in a healthcare setting. Official labeling notes that specific patient groups, such as those with impaired kidney function or volume depletion, are at increased risk for excessive, severe hypotension following an overdose, requiring heightened observation.

Therapeutic Uses of Narapril

What Narapril Treats: Main Uses and Benefits

Narapril is generally used for the long-term management of several chronic cardiovascular conditions. Its primary purpose is to provide therapeutic support that helps manage symptoms related to heightened physiological activity. The medication is applied across domains where additional symptomatic support is needed for systemic cardiovascular health.

It is commonly used to treat conditions characterized by periods of heightened symptoms, including essential hypertension, certain secondary hypertensions related to the kidneys, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction.


Managing Chronic Cardiovascular Conditions

Narapril is applied in addressing conditions marked by increased physiological stress, where a reduction in systemic pressure is relevant. This assists in managing the overall symptom load and may be part of symptomatic management that supports general well-being during symptomatic phases. For patients with heart dysfunction, this helps address symptom clusters that may become intense, such as chronic fatigue and shortness of breath. This supports general well-being during symptomatic phases and may assist with maintaining functional stability.

Quick Fact: Relief for Symptom Clusters Narapril is used to help manage symptoms related to physical discomfort, which supports the easing of symptoms like dyspnea and fatigue often associated with heart failure.

Eligibility and Restrictions for Use

Who Can and Cannot Use Narapril?

Narapril (Enalapril maleate) eligibility is strictly defined by regulatory documents, which establish specific populations for whom the medicine is contraindicated or not recommended.

Absolute Contraindications:

  • Patients with a history of Angioedema related to any Angiotensin-Converting Enzyme (ACE) inhibitor, or those with Hereditary or Idiopathic Angioedema.
  • Patients using Sacubitril/Valsartan (must not be taken within 36 hours of switching to or from Narapril).
  • Patients with Diabetes Mellitus or Renal Impairment (GFR less than 60 mL/min/1.73 m^2) who are concurrently taking Aliskiren.
  • Women in the second or third trimesters of pregnancy.

Restricted or Not Recommended Populations:

  • Use is Not Recommended during the first trimester of pregnancy and during breastfeeding.
  • Pediatric use is restricted: The medicine is Not Recommended in children under six years of age and is contraindicated in children with severe renal impairment (GFR less than 30 mL/min/1.73 m^2).
  • Patients with impaired renal function require close monitoring, and eligibility for use is conditional upon the need for dose adjustment.

What should I know about interactions with other medicines?

Narapril (enalapril) can interact with other medicines, affecting how both products work or increasing the risk of specific side effects. The most significant interactions involve other medicines that act on the cardiovascular and renal systems.

Major Contraindicated Combinations

  • Sacubitril-containing products: Concomitant use with medicines containing Sacubitril is strictly contraindicated due to a substantially increased risk of angioedema (rapid swelling of the face, neck, or tongue). A required 36-hour wash-out period must be observed before or after taking a Sacubitril-containing medicine.
  • Aliskiren: In patients diagnosed with diabetes, Narapril is contraindicated for use with any Aliskiren-containing product, as this combination increases the risk of hypotension, hyperkalemia, and worsening renal function.

Combinations Requiring Caution and Monitoring

  • Potassium-sparing diuretics and Potassium Supplements: Co-administration with potassium supplements, potassium-sparing diuretics (e.g., amiloride, spironolactone), or salt substitutes containing potassium can significantly elevate serum potassium levels (hyperkalemia). If necessary, this combination requires frequent monitoring of serum potassium.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs, including selective COX-2 inhibitors, may reduce Narapril's blood pressure-lowering effect and can increase the risk of hyperkalemia and renal function impairment, particularly in patients who are elderly, volume-depleted, or have pre-existing renal impairment.
  • Other Antihypertensive Agents: Combining Narapril with other blood pressure-lowering agents, such as thiazide-type diuretics, can result in additive hypotensive effects.

Mechanism of Action

Narapril is an inactive prodrug that undergoes rapid biotransformation in the liver via hydrolysis to its active metabolite, Naraprilat. This active form is a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I (Ang I) to the potent vasoconstrictor, angiotensin II (Ang II), within the Renin-Angiotensin-Aldosterone System (RAAS).

By binding to and blocking ACE, Naraprilat decreases the plasma concentration of Ang II. Reduced Ang II levels lead to two primary systemic physiological consequences: diminished vasoconstriction of arterioles and decreased aldosterone secretion from the adrenal cortex. Additionally, ACE is identical to kininase II, the enzyme responsible for degrading the vasodilatory peptide bradykinin. Inhibition of ACE therefore impedes the breakdown of bradykinin, which further contributes to vasodilation. The overall systemic effect is a reduction in total peripheral resistance and a decrease in sodium and water reabsorption in the kidneys.

Dosage and Administration Information

How to Use Narapril

Narapril (Enalapril maleate) is administered according to a structured protocol for the long-term management of chronic cardiovascular conditions. The administration instructions focus strictly on the route, precise dosing, and necessary adjustments for specific populations.

Administration and Dosage

The primary route of administration is oral, using tablets or a reconstituted solution. The active metabolite, Enalaprilat, is also available for intravenous use in acute clinical settings.

Indication Initial Adult Oral Dose Maximum Adult Daily Dose
Hypertension 5 mg once daily (or 2.5 mg with diuretic use) 40 mg
Heart Failure 2.5 mg once or twice daily 40 mg (divided doses)

Oral doses are typically administered once daily but may be split into two divided doses if indicated. The medication can be taken with or without food as absorption is not influenced by meals.

Procedural Conditions and Adjustments

Narapril therapy is initiated using a low dose, which is then gradually increased, or titrated, over a period of two to four weeks, particularly in heart failure management.

Population-Specific Rules:

  • Patients with renal impairment (Creatinine Clearance less than or equal to 30 mL/min) require a reduced initial dose of 2.5 mg once daily.
  • For patients on dialysis, the oral dose is 2.5 mg and should be administered only on dialysis days, following the procedure.

Special Constraint: Narapril must not be administered within 36 hours of taking a sacubitril/valsartan combination.

Recent Clinical Evidence

Narapril: Recent Clinical Evidence

Narapril (Enalapril maleate) was studied in major clinical trials and scientific reviews to investigate its activity in different cardiovascular conditions. The research provides context for how patients reported their experience and how physiological strain or stress was monitored across large groups of people.


Evidence for use in Essential Hypertension

The use of Narapril for high blood pressure was examined in a combination of Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored outcomes related to systemic imbalance, specifically changes in systolic and diastolic blood pressure readings. Research also examined whether Narapril was associated with differences in the rate of major cardiovascular events over several years. While high-level evidence suggests consistent patterns related to blood pressure change, the follow-up durations were limited in some comparative trials.


Evidence for use in Heart Failure

The study of Narapril for symptomatic heart failure involved large-scale, placebo-controlled RCTs. Research examined the impact on critical outcomes such as all-cause mortality and the prevention of hospitalization due to worsening heart failure. Findings describe patterns observed in the studies where researchers measured differences in the overall rate of death compared to the groups receiving placebo. For patients without symptoms, research explored whether the medicine was associated with a delay in the onset of symptomatic heart failure. A key research limitation frame is that the strongest evidence applies only to the populations studied with reduced pumping function (HFrEF); the evidence is limited for preserved function (HFpEF).


Research in Specific Patient Groups and Uncertainty

Narapril was evaluated in a limited number of trials focused on pediatric patients with high blood pressure, where findings were mixed and sample sizes were modest. The patterns of long-term outcomes are not fully established or consistent across all subgroups. Scientific reviews indicate that data for certain groups remain insufficient, and the long-term research includes limitations regarding comparative evidence when considering other treatment strategies for hypertension.

Key Studies & References The Studies of Left Ventricular Dysfunction (SOLVD) Prevention and Treatment Trials: Design and Methods

Frequently Asked Questions (FAQ)

Common questions about Narapril (FAQ)

Q: What is the main difference between Narapril and similar blood pressure medicines?

A: Narapril is classified by regulatory documents as an Angiotensin-Converting Enzyme (ACE) inhibitor, which works by affecting a specific hormonal pathway. It is also classified as a prodrug, meaning it starts in an inactive form and must be converted in the liver to its potent, active form, Enalaprilat.

Q: What evidence is there to support the use of Narapril for heart failure?

A: Official labeling indicates Narapril is used to treat symptomatic heart failure and asymptomatic left ventricular dysfunction. Studies show evidence of increased survival and a decreased frequency of hospitalization for patients in these patient populations.

Q: Does Narapril affect kidney function over time?

A: The official product information states that Narapril may be associated with impaired renal function, and official information notes that monitoring of kidney function may be necessary. Dose adjustments are indicated for patients with pre-existing kidney impairment, and the drug’s safety profile lists acute renal failure as a serious adverse reaction.

Q: Does Narapril cause coughing, and if so, why?

A: A cough is listed as a very common adverse reaction in regulatory documents. This specific reaction is associated with the way the medicine works by influencing the Angiotensin-Converting Enzyme (ACE) system.

Q: How often do I need follow-up blood tests while on Narapril?

A: Regulatory documents state that serum potassium and renal function levels may be subject to monitoring for individuals taking Narapril. This is especially important when the medication is combined with specific other medicines, such as potassium-sparing diuretics.

Q: Can I drink alcohol in moderation while using Narapril?

A: Official documents indicate that patients should be aware of the effects of alcohol consumption and its potential to cause additive blood pressure lowering effects. This effect can increase the risk of dizziness, lightheadedness, or fainting.

Q: Can I switch from one blood pressure medicine to Narapril?

A: The most crucial regulatory constraint on switching involves medicines containing Sacubitril. A 36-hour wash-out period is indicated by regulatory documents when switching to or from a Sacubitril-containing medicine to reduce the risk of angioedema (rapid swelling).

Q: If Narapril helps lower blood pressure, can I eventually stop taking it?

A: Narapril is generally indicated for the long-term management of chronic cardiovascular conditions, such as high blood pressure and heart failure. The decision to discontinue or change any long-term therapy is a clinical decision based on a complete assessment of individual patient needs.

Q: How long does it usually take to feel the effects of Narapril?

A: Following an oral dose, the medication is converted in the liver to its active form, Enalaprilat. The peak concentrations of this active form in the blood are generally reached approximately three to four hours after the tablet is taken, which is when the blood pressure-lowering effect is strongest.

Q: Do I need to change my diet while taking Narapril?

A: Official documents describe constraints regarding potassium-containing foods, supplements, and salt substitutes, due to the potential for increased potassium in the blood. This is because Narapril can influence the amount of potassium in the body, leading to a condition called hyperkalemia.

Q: What happens if I accidentally miss a dose of Narapril?

A: Regulatory information describes the procedure, stating that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is continued. Doubling a dose to make up for a missed one is not indicated.

Q: Is it normal to feel a mild headache when first starting Narapril?

A: Headache is listed as a common adverse reaction in regulatory documents, meaning it occurs in more than 1 out of 100 people. Headache is among the reactions reported in clinical trials.

Q: Can taking Narapril affect my ability to drive or operate machinery?

A: Narapril may cause side effects such as dizziness or faintness, particularly at the beginning of treatment. Official warnings state that due to the potential for dizziness or faintness, caution is indicated before driving or operating machinery, especially when first starting treatment.

Q: Is Narapril safe to use long-term?

A: Narapril is officially indicated for the long-term management of chronic cardiovascular conditions. While the medication is designed for chronic use, all long-term medication use requires periodic clinical evaluation.

Q: What is the risk of a severe allergic reaction to Narapril?

A: Regulatory documents list angioedema (swelling of the face, tongue, and throat) as a serious adverse reaction associated with this medication. Other severe allergic reactions are described in the official warnings and require immediate attention.

Q: Does Narapril interact with herbal supplements like St. John's Wort?

A: Official patient information advises that there is generally insufficient regulatory information on the safety of taking herbal remedies and complementary medicines with Narapril. Official documents state that patients are typically instructed to inform their healthcare provider of all supplements used.

Q: Does Narapril affect cholesterol levels?

A: Regulatory documents indicate that in clinical studies of patients with high blood pressure who had normal cholesterol levels, Narapril had no significant effect on plasma lipoprotein fractions (cholesterol).

Q: What are the signs of a drug interaction involving Narapril?

A: The signs of a potential drug interaction depend on the specific combination, but include: swelling of the face, tongue, and throat (angioedema); symptoms of very low blood pressure (dizziness, fainting); or symptoms of high potassium (muscle weakness or irregular heartbeat).

Q: Is Narapril used to prevent heart attacks or strokes?

A: Narapril is officially indicated for the management of high blood pressure and heart failure. Research evidence has examined its association with differences in the rate of major cardiovascular events over time.

Q: Can Narapril make me feel dizzy or lightheaded?

A: Yes, regulatory documents list dizziness as a very common or common side effect. Symptoms of low blood pressure (hypotension), such as lightheadedness or fainting, are also listed as common, especially when treatment is first started.

Q: Does Narapril lose its effect after long-term use?

A: Narapril is intended for the long-term, sustained management of chronic conditions. The medicine is generally observed to maintain its effect throughout the course of chronic therapy.

Q: Are there any known interactions between Narapril and cold/flu remedies?

A: Certain components of cold and flu remedies, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and some decongestants, may interact with Narapril. Official information notes that co-administration of these products may necessitate monitoring.

Q: What should I tell my dentist before a procedure if I am taking Narapril?

A: Official warnings note that healthcare providers, including dentists, should be informed about Narapril use. This is relevant because the medicine may increase the risk of low blood pressure (hypotension) during or after certain procedures, including those involving anesthesia.

Q: Does taking Narapril influence the results of other medical tests?

A: Yes, taking Narapril can influence the results of some tests. Specifically, it may lead to small increases in serum potassium levels. It may also affect the results of tests used to measure kidney function.

Q: Is the research on Narapril based on studies of long duration?

A: The research for Narapril's approved uses includes large-scale randomized controlled trials designed to study long-term outcomes like mortality and hospitalization. However, official documents indicate some comparative trials have limited follow-up durations.

Q: Why do some people experience fatigue when they first start Narapril?

A: Fatigue is listed as a common adverse reaction in regulatory documents. This may be linked to common effects like hypotension (low blood pressure), which can occur more frequently at the start of therapy as the body adjusts to the medication.

Q: What happens if I take Narapril with grapefruit juice?

A: Official patient information generally indicates no known interactions between Narapril (Enalapril) and common foods or drinks, including grapefruit juice.

Q: How does Narapril compare in safety profiles to other common blood pressure drugs?

A: Official documents describe Narapril's safety profile in detail, classifying it as an Angiotensin-Converting Enzyme (ACE) inhibitor. Its profile is specific to that drug class, including the characteristic risk of a dry cough and the serious risk of angioedema.

Q: What is the difference between a minor and a serious side effect of Narapril?

A: Regulatory documents categorize side effects by frequency and severity. Serious Adverse Reactions are those requiring immediate medical attention, such as angioedema or acute renal failure. These are distinct from common reactions like dizziness or headache.

Q: What is the research evidence theme behind using Narapril for kidney protection?

A: Research related to kidney function is a key element of Narapril's use because the medicine works by influencing the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS is a hormonal system that is highly important for regulating blood pressure and kidney function.

How should Narapril be stored and disposed of?

How to Store and Dispose of Narapril?

The storage and disposal of Narapril (Enalapril maleate) must strictly follow official regulatory requirements to maintain product stability and safety. The tablets must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). It is mandatory to keep the medication in its original container, ensuring it is tightly closed and protected from excessive moisture and heat; do not store in the bathroom or freeze. According to labeling, the product must always be secured and kept out of the sight and reach of children.

For disposal, unused or expired Narapril should not be flushed down a toilet or poured into a drain to prevent environmental contamination. Patients should consult a pharmacist or local authority for instruction on how to properly discard the medicine according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Narapril found in:

A-Z Index: